Soluble Interleukin 2 Receptor-Alpha (sIL-2Rα) in the Peripheral Blood of Dogs—Comparison of Malignant Neoplasia with Other Diseases

Christian Prachar, Franz-Josef Kaup, Stephan Neumann

.
Small Animal Clinic, Institute of Veterinary Medicine, University of Goettingen, Goettingen, Germany.

DOI: 10.4236/ojvm.2013.32027                

Abstract

Background: Cytokines are mediators of diseases. Expression levels in the blood could be of clinical relevance. Objective: sIL-2Rα is used as a marker for different malignancies in human medicine. The aim of this study was to show if sIL-2Rα is detectable and if there is any correlation to different diseases in dogs. Methods: For this purposes sIL-2Rα concentrations in the blood were measured in healthy dogs, in dogs with different non-neoplastic diseases and benign tumors and in dogs with malignant tumors. Serum levels of sIL-2Rα were measured by using a human specific enzyme linked immunosorbent assay (ELISA). Results: Measurement of sIL-2Rα was successful in most of the samples. Dogs with diseases have significantly increased serum levels of sIL-2Rα compared to healthy controls. sIL-2Rα serum levels are higher in patients with non-neoplastic diseases and benign tumors than in those with malignant neoplasia. There is a strong correlation between sIL-2Rα and leukocyte count. Conclusion: Measurements of sIL-2Rα in serum may be helpful in detecting stages and grades of inflammation in the progression of disease. sIL-2Rα could actually not be used as an indicator for malignant diseases in dogs like in humans. The strong correlation between sIL-2Rα and the leukocyte count indicates the inflammatory response to the disease. This could be helpful in giving a prognosis in some cases, because the inflammatory reaction is of prognostic relevance in different diseases including malignant and non-malignant neoplasia. Although the results of our research studies were very promising, further studies should be performed with a canine ELISA.

Keywords

sIL-2Rα; Soluble Interleukin-2 Receptor Alpha; ELISA; Dog

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	I. R. Tizard, “Veterinary Immunology,” Saunders, St. Louis/Missouri, 2008.
[2]	R. K. Gupta, M. Jain and R. K. Sharma, “Serum & Urinary Interleukin-2 Levels as Predictors in Acute Renal Allograft Rejection,” Indian Journal of Medical Research, Vol. 119, No. 5, 2004, p. 24-27.
[3]	P. H. Lee, et al., “Serum Interleukin-2 and Soluble Interleukin-2 Receptor in Renal Transplant Recipients,” Journal of the Formosan Medical Association, Vol. 91, No. 9, 1992, pp. 844-848.
[4]	R. Di Stefano, et al., “Interleukin-2 Receptor Levels in End-Stage Renal Disease and Transplant Patients,” Transplant Proceedings, Vol. 22, No. 4, 1990, pp. 1863-1864.
[5]	G. C. Zucchelli, et al., “Increased Circulating Concentrations of Interleukin 2 Receptor during Rejection Episodes in Heart- or Kidney-Transplant Recipients,” Clinical Chemistry, Vol. 36, No. 12, 1990, pp. 2106-2109.
[6]	E. Bien and A. Balcerska, “Serum Soluble Interleukin 2 Receptor Alpha in Human Cancer of Adults and Children: A Review,” Biomarkers, Vol. 13, No. 1, 2008, pp. 1-26. doi:10.1080/13547500701674063
[7]	N. El Houda Agueznay, et al., “Soluble Interleukin-2 Receptor and Metalloproteinase-9 Expression in Head and Neck Cancer: Prognostic Value and Analysis of Their Relationships,” Clinical and Experimental Immunology, Vol. 150, No. 1, 2007, pp. 114-123. doi:10.1111/j.1365-2249.2007.03464.x
[8]	E. Bargagli, et al., “Chitotriosidase and Soluble IL-2 Receptor: Comparison of Two Markers of Sarcoidosis Severity,” Scandinavian Journal of Clinical & Laboratory Investigation, Vol. 68, No. 6, 2008, pp. 479-483. doi:10.1080/00365510701854975
[9]	Z. Z. Yang, et al., “Soluble IL-2Ralpha Facilitates IL-2-Mediated Immune Responses and Predicts Reduced Survival in Follicular B-Cell Non-Hodgkin Lymphoma,” Blood, Vol. 118, No. 10, 2011, pp. 2809-2820. doi:10.1182/blood-2011-03-340885
[10]	S. H. Hsiao, et al., “Clinical Significance of Measuring Levels of Tumor Necrosis Factor-Alpha and Soluble Interleukin-2 Receptor in Nasopharyngeal Carcinoma,” Acta Otolaryngology, Vol. 129, No. 12, 2009, pp. 1519-1523. doi:10.3109/00016480902849427
[11]	T. Matsumoto, et al., “Serum Levels of Soluble Interleukin-2 Receptor in Renal Cell Carcinoma,” Urology, Vol. 51, No. 1, 1998, pp. 145-149. doi:10.1016/S0090-4295(97)00476-7
[12]	A. Lobo-Yeo, et al., “Soluble Interleukin 2 Receptors in Autoimmune Chronic Active Hepatitis,” Gut, Vol. 31, No. 6, 1990, pp. 690-693. doi:10.1136/gut.31.6.690
[13]	E. B. Dickerson, et al., “Potential to Target Dysregulated Interleukin-2 Receptor Expression in Canine Lymphoid and Hematopoietic Malignancies as a Model for Human Cancer,” Journal of Immunotherapy, Vol. 25, No. 1, 2002, pp. 36-45. doi:10.1097/00002371-200201000-00004
[14]	B. Brugos, et al., “Serum and Urinary Cytokine Levels of SLE Patients,” Pharmazie, Vol. 67, No. 5, 2012, pp. 411-413.
[15]	A. M. Berghella, et al., “The Significance of an Increase in Soluble Interleukin-2 Receptor Level in Colorectal Cancer and Its Biological Regulating Role in the Physiological Switching of the Immune Response Cytokine Network from TH1 to TH2 and Back,” Cancer Immunology, Immunotherapy, Vol. 45, No. 5, 1998, pp. 241-249. doi:10.1007/s002620050439
[16]	T. Akahane, et al., “Serum Soluble Interleukin-2 Receptor Levels in Patients with Malignant Lymphoma of Bone,” Journal of Orthopaedic Science, Vol. 14, No. 3, 2009, pp. 248-252. doi:10.1007/s00776-009-1335-x
[17]	A. Ottaiano, et al., “Soluble Interleukin-2 Receptor in Stage I-III Melanoma,” Cytokine, Vol. 33, No. 3, 2006, pp. 150-155. doi:10.1016/j.cyto.2006.01.002
[18]	G. Vitale, et al., “The Significance of Serum Soluble IL-2 Receptor as a Marker for Active Visceral Leishmaniasis in Sicilian Patients,” Clinical and Experimental Immunology, Vol. 90, No. 2, 1992, pp. 219-222. doi:10.1111/j.1365-2249.1992.tb07932.x
[19]	D. Dejica, “Serum Soluble IL-2 Receptor as a Marker of Lymphocyte Activation in Some Autoimmune Diseases. Effect of Immunosuppressive Therapy,” Roumanian Archives of Microbiology and Immunology, Vol. 60, No. 3, 2001, pp. 183-201.
[20]	M. R. Peterson, R. A. Frommelt and D. G. Dunn, “A Study of the Lifetime Occurrence of Neoplasia and Breed Differences in a Cohort of German Shepherd Dogs and Belgian Malinois Military Working Dogs That Died in 1992,” Journal of Veterinary Internal Medicine, Vol. 14, No. 2, 2000, pp. 140-145. doi:10.1111/j.1939-1676.2000.tb02227.x
[21]	H. Eichelberg and R. Seine, “Lebenserwartung und Todesursachen bei Hunden-I. Zur Situation bei Mischlingen und Verschiedenen Rassen,” Berliner und Munchener Tierarztliche Wochenschrift, Vol. 109, No. 8, 1996, pp. 292-303.
[22]	A. R. Michell, “Longevity of British Breeds of Dog and Its Relationships with Sex, Size, Cardiovascular Variables and Disease,” Veterinary Record, Vol. 145, No. 22, 1999, pp. 625-629. doi:10.1136/vr.145.22.625
[23]	T. Morito, et al., “Serum Soluble Interleukin-2 Receptor Level and Immunophenotype Are Prognostic Factors for Patients with Diffuse Large B-Cell Lymphoma,” Cancer Science, Vol. 100, No. 7, 2009, pp. 1255-1260. doi:10.1111/j.1349-7006.2009.01167.x
[24]	A. M. Witkowska, “On the Role of sIL-2R Measurements in Rheumatoid Arthritis and Cancers,” Mediators of Inflammation, Vol. 2005, No. 3, 2005, pp. 121-130. doi:10.1155/MI.2005.121
[25]	M. S. Akash, K. Rehman and S. Chen, “Role of Inflammatory Mechanisms in Pathogenesis of Type 2 Diabetes Mellitus,” Journal of Cellular Biochemistry, Vol. 114, No. 3, 2012, pp. 525-531.
[26]	B. Baumann, H. H. Salem and B. O. Boehm, “Anti-Inflammatory Therapy in Type 1 Diabetes,” Current Diabetes Reports, Vol. 12, No. 5, 2012, pp. 499-509. doi:10.1007/s11892-012-0299-y
[27]	C. J. Kelly, “T Cell Function in Chronic Renal Failure and Dialysis,” Blood Purif, Vol. 12, No. 1, 1994, pp. 36-41. doi:10.1159/000170143
[28]	K. H. Shu, et al., “Soluble Interleukin 2 Receptor in Dialyzed Patients,” Artif Organs, Vol. 22, No. 2, 1998, pp. 142-144. doi:10.1046/j.1525-1594.1998.05062.x
[29]	H. Sugimoto, et al., “The Clinical Significance of the Measurement of Serum Soluble Interleukin-2 Receptors in Various Diseases,” Rinsho Byori, Vol. 44, No. 2, 1996, pp. 176-182.